Six leading research organizations in Latvia have joined forces to establish the BioMedPharm consortium, a pioneering platform capable of implementing biomedical research projects of any complexity. The idea for the BioMedPharm consortium was conceived a year ago as a project proposal for the Innovation Fund Program of the Ministry of Economics. What began as a temporary project has now evolved into a robust and permanent entity.
Institute of Food Safety, Animal Health and Environment “BIOR”, Latvian Biomedical Research and Study Center, Latvian Institute of Organic Synthesis, Riga Stradiņš University, Riga Technical University, and University of Latvia are founders of the BioMedPharm.
BioMedPharm’s core mission is to enhance patient access to treatment, thereby reducing mortality and morbidity rates and improving overall health conditions. The consortium will focus on developing medicinal products and their manufacturing technologies, transport forms, vaccines, drug repurposing, drug discovery and development, as well as identifying new biomarkers and precision medicine solutions.
“We have identified numerous complementarities that enable platform members to address multidisciplinary research challenges. Existing research partnerships were strengthened, and new ones were established,” said Osvalds Pugovičs, one of the initiators of BioMedPharm. “And most importantly, we have developed mutual trust in partners’ competence and reliability. In today’s multidisciplinary world of biomedical science, this trust stands as the most valuable asset one could desire.”
BioMedPharm aims not only to develop essential treatment solutions for patients in Latvia but also to support the country’s pharmaceutical industry on its way to international success. Moreover, BioMedPharm is committed advancing in basic science by addressing fundamental research challenges.
“We are excited to announce the official establishment of BioMedPharm on October 12th. This marks a significant milestone in our journey to foster biomedical research in Latvia,” added Osvalds Pugovičs.
The signing of the Memorandum of Understanding between the most advanced biomedicine research organizations of Latvia solidifies BioMedPharm’s commitment to long-term collaboration. Sharing best practices and contributing to the advancement of research management BioMedPharm aspires to become a social partner in science policy-making communities.
BioMedPharm wishes to thank PMNet Forum for its support in making this momentous event public and expresses sincere appreciation to the Ministry of Economics for its understanding and support given so far.